BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35383486)

  • 21. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
    Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
    Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
    Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
    AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
    [No Abstract]   [Full Text] [Related]  

  • 27. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma.
    Fetzer DT; Rodgers SK; Seow JH; Dawkins AA; Joshi G; Gabriel H; Kamaya A
    Radiol Clin North Am; 2019 May; 57(3):563-583. PubMed ID: 30928078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interobserver Agreement Between Primary Sonographers and Secondary Overreaders for Screening and Surveillance Liver Ultrasounds Using Ultrasound Liver Imaging Reporting and Data System.
    Dawkins A; Nelson LW; Gulati V; Stepp A; Chapelin F; Khurana A
    Ultrasound Q; 2022 Jun; 38(2):116-123. PubMed ID: 35678479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System.
    Fetzer DT; Rodgers SK; Harris AC; Kono Y; Wasnik AP; Kamaya A; Sirlin C
    Radiol Clin North Am; 2017 Nov; 55(6):1197-1209. PubMed ID: 28991560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.
    Darnell A; Forner A; Rimola J; Reig M; García-Criado Á; Ayuso C; Bruix J
    Radiology; 2015 Jun; 275(3):698-707. PubMed ID: 25658038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol.
    da Silva PH; Gomes MM; de Matos CAL; de Souza E Silva IS; Gonzalez AM; Torres US; Salazar GMM; D'Ippolito G
    J Ultrasound Med; 2021 Nov; 40(11):2487-2495. PubMed ID: 33463734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis.
    Quek J; Tan DJH; Chan KE; Lim WH; Ng CH; Ren YP; Koh TK; Teh R; Xiao J; Fu C; Syn N; Teng M; Muthiah M; Fowler KJ; Sirlin CB; Loomba R; Huang DQ
    Dig Dis; 2023; 41(5):757-766. PubMed ID: 37231918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study.
    Ranathunga D; Osman H; Islam N; McInnes MDF; Munir J; van der Pol CB; Elfaal M; Walsh C
    AJR Am J Roentgenol; 2022 Mar; 218(3):462-470. PubMed ID: 34643108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.